Berlin - Delayed Quote EUR

Isoray Inc (AAJ.BE)

1.4700

-0.0800

(-5.16%)

At close: April 26 at 8:08 AM GMT+2

Perspective Therapeutics to Participate at Upcoming April Investor Conferences

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April. Thijs Spoor, Chief Executive Officer, will be participating in a panel discussion titled Radiopharmaceuticals: Energizing Disruption in Therapeutics, at the Goldman Sachs Third Annu

GlobeNewswire 19 days ago
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023. “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha

GlobeNewswire 30 days ago
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma

SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety and tolerability of Perspective’s targeted alpha-particle therapy [212Pb]VMT01 in combination with Bristol Myers Squibb’s nivolumab in patients with histologically confi

GlobeNewswire last month
Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024

SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET. To register, click here. The event will feature presentations from the following members of the Company’s manag

GlobeNewswire last month
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility

SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the consummation of the acquisition of a state-of-the-art manufacturing facility and associated equipment and systems for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals. Previously operated by Lantheus Holdings, Inc. (

GlobeNewswire last month
Perspective Therapeutics Announces $87.4 Million Private Placement

SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has entered into an investment agreement with a select group of institutional accredited investors, to sell securities in a private placement for aggregate gross proceeds of approximately $87.4 million, before deducting placement a

GlobeNewswire last month
Perspective Therapeutics to Participate at Upcoming Investor Conferences

SEATTLE, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that management will participate at upcoming discussions and investor conferences in February and March, 2024. Fireside Chat with JonesResearch – February 28, virtualTime: 11 a.m. ETParticipant: Michael K. Schultz, Ph.D., Chief Science Offi

GlobeNewswire last month
Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024, at 11:20 a.m. ET. Management will also be available for one-on-one meeting

GlobeNewswire 2 months ago
Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform

Signs a World-Wide Exclusive License with Stony Brook University for a Novel Platform that can Enhance Radionuclide TargetingReceives up to $2.4M NIH Grant to Develop Differentiated Antibody-based Radiopharmaceutical Approach SEATTLE, Feb. 01, 2024 (GLOBE NEWSWIRE) -- -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has

GlobeNewswire 2 months ago
Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement

SEATTLE, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the closing of its previously announced underwritten public offering of (i) 156,399,542 shares of its common stock at the public offering price of $0.37 per share, including the exercise in full by the underwriters of their option to purcha

GlobeNewswire 3 months ago
Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

SEATTLE, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten public offering of 132,075,218 shares of its common stock at a public offering price of $0.37 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 30,086,944 shares of i

GlobeNewswire 3 months ago
Perspective Therapeutics Announces Proposed Public Offering

SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has commenced an underwritten public offering of shares of its common stock, and, to certain investors in lieu of common stock, pre-funded warrants to purchase shares of its common stock. The purchase price of each pre-funded warran

GlobeNewswire 3 months ago
Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01

SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced that it began patient recruitment for the second dosing cohorts (Cohort 2) in clinical studies for both of its lead product candidates, [212Pb]VMT-α-NET and [212Pb]VMT01, after the safety monitoring committees for each study unanimously recommended moving forward. In addition, the first patient in cohort 2 of the [212Pb]VMT01 study was already dosed. [212Pb]VMT-α-NET is a targeted alp

GlobeNewswire 3 months ago
Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability

Lantheus will have the option to negotiate an exclusive license to Perspective Therapeutics’ Pb212-VMT-α-NETLantheus will have the option to co-fund and negotiate an exclusive license for certain early-stage therapeutic candidates targeting prostate cancer using Perspective’s lead platform technologyLantheus agrees to invest up to approximately $33 million in Perspective Therapeutics equity subject to Perspective Therapeutics’ completion of a qualifying third-party financing transactionPerspecti

GlobeNewswire 3 months ago
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics

Option to license Perspective Therapeutics’ Pb212-VMT-α-NET asset Co-development rights for certain Pb212-based alpha therapies for prostate cancer Equity investment of up to 19.9% in Perspective Therapeutics Perspective Therapeutics intends to acquire Somerset, NJ radiopharmaceutical manufacturing facility BEDFORD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) today announced it has entered into multiple strategic agreements with Perspective Therapeu

GlobeNewswire 3 months ago
Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

Mayo Clinic’s PSMA Alpha-PET DoubLET platform allows for imaging and targeted therapy with alpha and/or beta-particle radiopharmaceutical therapy (RPT) using a novel 64/67Cu and 203/212Pb double chelator design.PSMA Alpha-PET DoubLET licensing provides Perspective with a strongly differentiated prostate cancer program SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that it has entered into a patent

GlobeNewswire 3 months ago
Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs Spoor, the Company’s Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 11, 2024, at 12 p.m. PT. Management will also participate at investor conferences alongside the J.P. Morgan Healthcare Conference in San Francisco. 42nd Annual J.P. Morgan Healthcare Confe

GlobeNewswire 3 months ago
Perspective Therapeutics Divests Brachytherapy Business

SEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced it agreed to fully divest its brachytherapy business, including its radioactive Cesium-131 seed assets and related business infrastructure, to GT Medical Technologies, Inc. (“GT Medical”). The transaction is expected to close in the first quarter of 2024 and is subject to customary closing conditions. Under the terms of the transaction, Isoray Medical,

GlobeNewswire 4 months ago
$Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors$
Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors

First U.S. patient with refractory or relapsed SSTR2-positive neuroendocrine tumors treated with [212Pb]VMT-α-NETPreliminary data readout expected in second half of 2024 SEATTLE, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at the University of Iowa in an investigator-initiated Phase 1 trial evaluating the safety of [212Pb]VMT-α-NET, a targeted alpha-particle therapy (TAT)

GlobeNewswire 4 months ago
Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT-α-NET by Clinical Collaborators in Germany

Imaging was conducted as part of a clinical study at Technical University of Dresden in GermanyImage was selected as “Image of the Month” in the European Journal of Nuclear Medicine and Molecular Imaging, November 2023Radiolabeling was performed on-site using a Company-provided generator SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the publication of the first human SPECT images utilizing the alp

GlobeNewswire 4 months ago

Performance Overview

Return	AAJ.BE	S&P 500
YTD	+255.07%	+6.92%
1-Year	+153.45%	+25.26%
3-Year	+104.17%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Isoray Inc (AAJ.BE)

Perspective Therapeutics to Participate at Upcoming April Investor Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma

Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024

Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility

Perspective Therapeutics Announces $87.4 Million Private Placement

Perspective Therapeutics to Participate at Upcoming Investor Conferences

Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform

Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement

Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

Perspective Therapeutics Announces Proposed Public Offering

Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01

Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability

Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics

Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics Divests Brachytherapy Business

Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT-α-NET by Clinical Collaborators in Germany

Performance Overview